Abstract
This invention relates to a method of treating damage to the central nervous system, comprising administering a pharmaceutically-effective amount of a CCR5 antagonist, and a pharmaceutically effective amount of an AQP4 antagonist, or pharmaceutically acceptable salts thereof.
Original language | English |
---|---|
Patent number | US2024131033 |
IPC | A61P 25/ 00 A I |
Priority date | 17/02/21 |
Publication status | Published - 25 Aug 2022 |